Titan Pharmaceuticals, Inc. (TTNP)

US — Healthcare Sector
Peers: AYTU  CMRA  OGEN  SNTI  VRPX  VTVT 

Automate Your Wheel Strategy on TTNP

With Tiblio's Option Bot, you can configure your own wheel strategy including TTNP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TTNP
  • Rev/Share 0.0094
  • Book/Share 2.6178
  • PB 1.6425
  • Debt/Equity 0.0
  • CurrentRatio 11.6008
  • ROIC -0.9365

 

  • MktCap 5719856.0
  • FreeCF/Share -2.5784
  • PFCF -2.083
  • PE -1.6326
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -1.0855

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

URGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)
TTNP
Published: July 29, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Titan Pharmaceuticals, Inc. (Nasdaq: TTNP ), relating to its proposed merger with BSKE Ltd. Under the terms of the agreement, Titan shareholders are expected to own approximately 13.3% of the combined company. Is it a fair deal?

Read More
image for news URGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)
Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.
TTNP
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec Sdn. Bhd. (f/k/a KE Sdn. Bhd.) (“TalenTec”), which includes Titan's preliminary proxy statement (the “Form F-4”)

Read More
image for news Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.

About Titan Pharmaceuticals, Inc. (TTNP)

  • IPO Date 1996-01-18
  • Website https://www.titanpharm.com
  • Industry Biotechnology
  • CEO Weei Jye Chay
  • Employees 4
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.